

Markus Mschen

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5298370/markus-muschen-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

177
papers

4,001
citations

38
h-index

61
g-index

181
ext. papers

5,119
ext. citations

9.6
avg, IF

5.05
L-index

#	Paper	IF	Citations
177	RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2014 , 46, 116-25	36.3	244
176	Histone H3 trimethylation at lysine 36 guides mA RNA modification co-transcriptionally. <i>Nature</i> , 2019 , 567, 414-419	50.4	232
175	Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. <i>Cell</i> , 2008 , 135, 1130-42	56.2	183
174	BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. <i>Nature</i> , 2011 , 473, 384-8	50.4	154
173	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016 , 29, 574-586	24.3	154
172	Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. <i>Cancer Cell</i> , 2020 , 38, 79-96.e11	24.3	145
171	The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. <i>Cancer Cell</i> , 2009 , 16, 232-45	24.3	122
170	Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. <i>Nature Immunology</i> , 2015 , 16, 766-774	19.1	121
169	Metabolic gatekeeper function of B-lymphoid transcription factors. <i>Nature</i> , 2017 , 542, 479-483	50.4	119
168	Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. <i>Journal of Experimental Medicine</i> , 2009 , 206, 1739-53	16.6	108
167	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. <i>Nature</i> , 2015 , 521, 357-61	50.4	90
166	Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. <i>Blood</i> , 2011 , 118, 2191-9.2.2		89
165	BCL6 is critical for the development of a diverse primary B cell repertoire. <i>Journal of Experimental Medicine</i> , 2010 , 207, 1209-21	16.6	89
164	MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. <i>Cell Reports</i> , 2015 , 13, 2715-27	10.6	84
163	BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. <i>Nature Medicine</i> , 2013 , 19, 1014-22	50.5	82
162	Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. <i>Cancer Cell</i> , 2015 , 27, 409-25	24.3	81
161	Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015 , 28, 114-28	24.3	78

160	MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. <i>Blood</i> , 2015 , 126, 2202-12	2.2	75
159	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. <i>Nature Medicine</i> , 2016 , 22, 379-87	50.5	74
158	Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. <i>Cancer Discovery</i> , 2012 , 2, 1004-23	24.4	70
157	Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. <i>Blood</i> , 2015 , 126, 1813-22	2.2	65
156	Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E2219-28	11.5	64
155	Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. <i>Immunity</i> , 2007 , 26, 323-33	32.3	63
154	B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. <i>Cell</i> , 2018 , 173, 470-484.e18	56.2	62
153	Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. <i>Journal of Experimental Medicine</i> , 2005 , 201, 1837-52	16.6	61
152	Inhibition of IRE1 β -driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. <i>Oncotarget</i> , 2016 , 7, 18736-49	3.3	60
151	Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. <i>Science Signaling</i> , 2011 , 4, ra18	8.8	52
150	Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. <i>Journal of Clinical Investigation</i> , 2017 , 127, 2392-2406	15.9	49
149	Ibrutinib inhibits pre-BCR B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. <i>Blood</i> , 2017 , 129, 1155-1165	2.2	47
148	R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/mA/PFKP/LDHB axis. <i>Molecular Cell</i> , 2021 , 81, 922-939.e9	17.6	46
147	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. <i>Nature Immunology</i> , 2017 , 18, 694-704	19.1	45
146	Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. <i>Molecular Systems Biology</i> , 2017 , 13, 914	12.2	44
145	Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. <i>Cell Reports</i> , 2018 , 23, 3127-3136	10.6	44
144	Infection Exposure Promotes Precursor B-cell Leukemia via Impaired H3K4 Demethylases. <i>Cancer Research</i> , 2017 , 77, 4365-4377	10.1	43
143	Circadian clock cryptochrome proteins regulate autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 12548-12553	11.5	43

142	Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 13266-71	11.5	43
141	BCL6 promotes glioma and serves as a therapeutic target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 3981-3986	11.5	38
140	Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. <i>Journal of Immunology</i> , 2005 , 174, 367-75	5.3	38
139	CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	37
138	Extrafollicular CD4 T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. <i>Nature Communications</i> , 2017 , 8, 978	17.4	35
137	Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2015 , 6, 6471	17.4	31
136	Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 2836-2841	11.5	30
135	Autoimmunity checkpoints as therapeutic targets in B cell malignancies. <i>Nature Reviews Cancer</i> , 2018 , 18, 103-116	31.3	29
134	Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. <i>Blood</i> , 2015 , 125, 3688-93	2.2	28
133	Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia. <i>Immunological Reviews</i> , 2015 , 263, 192-209	11.3	27
132	Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. <i>Current Opinion in Hematology</i> , 2014 , 21, 341-9	3.3	26
131	YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 39	22.4	25
130	BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint. <i>Trends in Immunology</i> , 2014 , 35, 131-7	14.4	25
129	Loss of Pax5 Exploits Sca1-BCR-ABL Susceptibility to Confer the Metabolic Shift Essential for pB-ALL. <i>Cancer Research</i> , 2018 , 78, 2669-2679	10.1	24
128	Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1 pre-B ALL. <i>Journal of Experimental Medicine</i> , 2017 , 214, 793-814	16.6	21
127	Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016 , 174, 425-36	4.5	21
126	Metabolic gatekeepers to safeguard against autoimmunity and oncogenic B cell transformation. <i>Nature Reviews Immunology</i> , 2019 , 19, 337-348	36.5	19
125	IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. <i>Nature</i> , 2020 , 588, 491-497	50.4	19

124	Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. <i>Blood</i> , 2016 , 127, 2131-43	2.2	18
123	Signalling input from divergent pathways subverts B-cell transformation. <i>Nature</i> , 2020 , 583, 845-851	50.4	16
122	Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. <i>Blood</i> , 2019 , 133, 306-318	2.2	16
121	Core transcriptional regulatory circuitries in cancer. <i>Oncogene</i> , 2020 , 39, 6633-6646	9.2	15
120	Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Neoplasia</i> , 2017 , 19, 750-761	6.4	14
119	Integrin β mediates the drug resistance of acute lymphoblastic B-cell leukemia. <i>Blood</i> , 2020 , 136, 210-223.	2	14
118	CAMKs support development of acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 30	22.4	13
117	IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia. <i>Blood</i> , 2020 , 136, 1520-1534	2.2	13
116	Infectious stimuli promote malignant B-cell acute lymphoblastic leukemia in the absence of AID. <i>Nature Communications</i> , 2019 , 10, 5563	17.4	12
115	Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL. <i>Scientific Reports</i> , 2014 , 4, 6565	4.9	11
114	Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia. <i>Blood</i> , 2019 , 134, 1257-1268	2.2	11
113	Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors. <i>Cell Reports</i> , 2017 , 18, 1687-1698	10.6	10
112	B-cell identity as a metabolic barrier against malignant transformation. <i>Experimental Hematology</i> , 2017 , 53, 1-6	3.1	10
111	Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Nature Communications</i> , 2020 , 11, 3194	17.4	9
110	Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021 , 12, 3526	17.4	9
109	Coactivation of NF- κ B and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion. <i>Blood</i> , 2020 , 135, 108-120	2.2	8
108	Rationale for targeting BCL6 in -rearranged acute lymphoblastic leukemia. <i>Genes and Development</i> , 2019 , 33, 1265-1279	12.6	8
107	mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph and Ph-like B-ALL. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1942-1953	6.1	6

106	Human lymphoid translocation fragile zones are hypomethylated and have accessible chromatin. <i>Molecular and Cellular Biology</i> , 2015 , 35, 1209-22	4.8	6
105	Infection and the Perils of B-cell Activation. <i>Cancer Discovery</i> , 2015 , 5, 1244-6	24.4	5
104	Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. <i>Molecular Cell</i> , 2021 , 81, 2094-2111.e9	17.6	5
103	High-resolution characterization of gene function using single-cell CRISPR tiling screen. <i>Nature Communications</i> , 2021 , 12, 4063	17.4	5
102	Ifitm3 (CD225) Mediates CD19-Dependent Survival and Proliferation During Normal B Cell Development and In Ph+ ALL. <i>Blood</i> , 2013 , 122, 2505-2505	2.2	4
101	mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL. <i>Blood</i> , 2016 , 128, 2763-2763	2.2	4
100	Topography of transcriptionally active chromatin in glioblastoma. <i>Science Advances</i> , 2021 , 7,	14.3	4
99	Metabolic Gatekeepers of Pathological B Cell Activation. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021 , 16, 323-349	34	4
98	An instructive role for Interleukin-7 receptor in the development of human B-cell precursor leukemia. <i>Nature Communications</i> , 2022 , 13, 659	17.4	3
97	CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 1434-1434	2.2	3
96	Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 2529-2529	2.2	3
95	PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	3
94	Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies. <i>Blood</i> , 2018 , 132, 547-547	5.47	2
93	Bruton's Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 1399-1399	2.2	2
92	BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 1456-1456	2.2	2
91	Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated Dual Synthetic Lethality To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor Cells. <i>Blood</i> , 2013 , 122, 810-810	2.2	2
90	IFITM3 (CD225) Links the B Cell Antigen CD19 to PI3K-AKT Signaling in Human ALL Cells. <i>Blood</i> , 2015 , 126, 1325-1325	2.2	2
89	CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies. <i>Blood</i> , 2016 , 128, 4088-4088	2.2	2

88	Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses. <i>Nature Communications</i> , 2021 , 12, 6522	17.4	2
87	CRISPR/Cas9-mediated gene deletion efficiently retards the progression of Philadelphia-positive acute lymphoblastic leukemia in a p210 BCR-ABL1 mutation mouse model. <i>Haematologica</i> , 2020 , 105, e232-e236	6.6	2
86	Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell Malignancies. <i>Blood</i> , 2018 , 132, 3922-3922	2.2	1
85	DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell Survival. <i>Blood</i> , 2011 , 118, 1479-1479	2.2	1
84	Targeting the UPR-Transcription Factor XBP1 to Overcome Drug-Resistance in Ph+ ALL. <i>Blood</i> , 2012 , 120, 872-872	2.2	1
83	Gas7 Induces The Proliferation Of Ph+ ALL Cells and Prevents The Differentiation Of Early B Cell Progenitors Into CD25high Small Pre-B Cells. <i>Blood</i> , 2013 , 122, 2506-2506	2.2	1
82	Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199. <i>Blood</i> , 2013 , 122, 3919-3919	2.2	1
81	Circadian Clock Protein CRY Controls B-Cell Intrinsic Tolerance. <i>Blood</i> , 2015 , 126, 1029-1029	2.2	1
80	Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin alpha6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10. <i>Blood</i> , 2015 , 126, 2525-2525	2.2	1
79	Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021 , 138, 616-616	2.2	1
78	IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation. <i>Blood</i> , 2018 , 132, 552-552	2.2	1
77	Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis. <i>Blood</i> , 2019 , 134, 2782-2782	2.2	1
76	Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions. <i>Blood</i> , 2019 , 134, 746-746	2.2	1
75	PP2A Balances Glucose Metabolism and Foxo Activation to Maintain Cellular Redox Homeostasis in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016 , 128, 1056-1056	2.2	1
74	The Tumor Suppressor PTEN Is Required to Prevent Cellular Senescence and Cell Cycle Arrest In B Cell Lineage and Chronic Myeloid Leukemia. <i>Blood</i> , 2010 , 116, 513-513	2.2	1
73	Pre-B Cell Receptor Signaling Distinguishes E2A-PBX1 From Other Subtypes of Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010 , 116, 274-274	2.2	1
72	BCOR Is Involved in Myeloid Cell Growth Control by Regulating Hox Genes. <i>Blood</i> , 2012 , 120, 3445-3445	2.2	1
71	Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1820-1835	6.1	1

70	Portending death in germinal centers - when B cells know their time is up. <i>Cell Research</i> , 2018 , 28, 5-6	24.7	1
69	TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. <i>Nature Communications</i> , 2021 , 12, 5337	17.4	1
68	BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia. <i>Blood</i> , 2010 , 116, 202-202	2.2	0
67	Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose Metabolism. <i>Blood</i> , 2016 , 128, 4069-4069	2.2	0
66	Fusions Drive Oncogenic Pre-BCR Signaling in B-ALL. <i>Blood Cancer Discovery</i> , 2020 , 1, 18-20	7	0
65	SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies.. <i>Cellular Signalling</i> , 2022 , 110331	4.9	0
64	Chemical choreography of germinal center B-cell migration. <i>Cell Research</i> , 2019 , 29, 514-515	24.7	
63	CCND3 is indispensable for the maintenance of B-cell acute lymphoblastic leukemia.. <i>Oncogenesis</i> , 2022 , 11, 1	6.6	
62	Beta-Catenin Forms Repressive Complexes with Ikzf1 and Ikzf3 to Orchestrate Tumor-Suppression in B-Cell Malignancies. <i>Blood</i> , 2021 , 138, 29-29	2.2	
61	Identification of a Conserved Intracellular Loop (CIL) Structure That Scaffolds PIP3 to Amplify Oncogenic Signaling during Malignant B-Cell Transformation. <i>Blood</i> , 2021 , 138, 868-868	2.2	
60	Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell Transformation. <i>Blood</i> , 2021 , 138, 792-792		
59	Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid Malignancies. <i>Blood</i> , 2021 , 138, 355-355	2.2	
58	Autoimmunity Checkpoints As Therapeutic Targets in B- and T-Cell Malignancies. <i>Blood</i> , 2017 , 130, 718-718		
57	PON2 Exemplifies a Unique Dependency of B Cell Lineage ALL Cells on Detoxifying Lactonases. <i>Blood</i> , 2017 , 130, 882-882	2.2	
56	Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018 , 132, 568-568	2.2	
55	Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors. <i>Blood</i> , 2018 , 132, 1411-1411		
54	Autoimmunity Checkpoints As Therapeutic Targets in B-Cell Malignancies. <i>Blood</i> , 2018 , 132, 1587-1587	2.2	
53	Pre-BCR Surrogate Light Chain Components VPBEB1 and IGLL1 Function As Pre-BCR-Independent Tumor Suppressors in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018 , 132, 570-570	2.2	

52	Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling. <i>Blood</i> , 2019 , 134, 393-393	2.2
51	Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL. <i>Blood</i> , 2019 , 134, 3785-3785	
50	Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation. <i>Blood</i> , 2019 , 134, 3944-3944	2.2
49	Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies. <i>Blood</i> , 2019 , 134, 295-295	2.2
48	Autonomous Ca ²⁺ Oscillations Reflect Oncogenic Signaling in B-ALL Cells. <i>Blood</i> , 2019 , 134, 1253-1253	2.2
47	Identification of ZNF217 As an Essential Oncogenic Gene in B-Cell Acute Lymphoblastic Leukemia By CRISPR/Cas9-Based Library Screening. <i>Blood</i> , 2019 , 134, 1465-1465	2.2
46	Rationale for Targeting BCL6 in MLL-Rearranged B-ALL. <i>Blood</i> , 2019 , 134, 1239-1239	2.2
45	Lgr5 Functions As a Critical Negative Regulator of Wnt/ β Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation. <i>Blood</i> , 2019 , 134, 748-748	2.2
44	Exposure to Inflammatory Immune Responses As Driver of Clonal Evolution in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 166-166	2.2
43	Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair Inhibitors. <i>Blood</i> , 2015 , 126, 50-50	2.2
42	B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic Signaling. <i>Blood</i> , 2015 , 126, 1255-1255	2.2
41	Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 3716-3716	2.2
40	Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation. <i>Blood</i> , 2015 , 126, 1875-1875	2.2
39	Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 556-556	2.2
38	PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 902-902	2.2
37	IFITM3 Is a Central Regulator of Lipid Raft Signaling and Essential for CD19 Surface Expression and PI3K Signaling in Human B Cell Malignancies. <i>Blood</i> , 2016 , 128, 2738-2738	2.2
36	Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted Treatments. <i>Blood</i> , 2016 , 128, 4077-4077	2.2
35	Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016 , 128, 2771-2771	2.2

- 34 Transcriptional Control of Glucose and Energy Supply Prevents Oncogenic Signaling and B Cell Transformation. *Blood*, **2016**, 128, 437-437 2.2
- 33 Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-Rearranged Acute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 907-907 2.2
- 32 BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation. *Blood*, **2016**, 128, 438-438 2.2
- 31 IKAROS and BCL6 Limit Pre-B Cell Expansion and Prevent Leukemogenesis Downstream of the Pre-B Cell Receptor. *Blood*, **2010**, 116, 146-146 2.2
- 30 IL7R β Signaling Prevents Premature Expression of AID In Human Pre-B Cells: Implications for Clonal Evolution of Childhood Leukemia. *Blood*, **2010**, 116, 26-26 2.2
- 29 SYK Is a Tumor Suppressor In Pre-B Cell Acute Lymphoblastic Leukemia and Not a Therapeutic Target. *Blood*, **2010**, 116, 4199-4199 2.2
- 28 Mechanisms of Pre-B Cell Receptor-Inactivation In Acute Lymphoblastic Leukemia. *Blood*, **2010**, 116, 147-147 2.2
- 27 BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia. *Blood*, **2011**, 118, 446-446 2.2
- 26 Targeting Inhibitory Phosphatases in Tyrosine Kinase-Driven Leukemias. *Blood*, **2011**, 118, 1382-1382 2.2
- 25 Infectious Origins of Childhood Leukemia. *Blood*, **2011**, 118, 751-751 2.2
- 24 Mechanisms of Ikaros-Mediated Tumor Suppression. *Blood*, **2011**, 118, 408-408 2.2
- 23 Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYC. *Blood*, **2011**, 118, 1406-1406 2.2
- 22 BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia. *Blood*, **2011**, 118, 562-562 2.2
- 21 Compensatory Signaling From ROR1 and the Pre-B Cell Receptor Promote Survival of t(1;19) Acute Lymphoblastic Leukemia. *Blood*, **2011**, 118, 2466-2466 2.2
- 20 Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia. *Blood*, **2011**, 118, 2490-2490 2.2
- 19 SOX4 enables Oncogenic Survival Signals in Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 863-863 2.2
- 18 BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance. *Blood*, **2012**, 120, 1300-1300 2.2
- 17 Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL. *Blood*, **2012**, 120, 2563-2563 2.2

- 16 Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL. *Blood*, **2012**, 120, 776-776 2.2
- 15 Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases. *Blood*, **2012**, 120, 1352-1352 2.2
- 14 BCL6 Interacting Corepressor (BCOR) Functions As Lineage-Specific Tumor Suppressor in B Lymphoid and Myeloid Leukemia. *Blood*, **2012**, 120, 1301-1301 2.2
- 13 ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALL. *Blood*, **2012**, 120, 291-291 2.2
- 12 Lineage-Specific Functions of LKB1 in CML and B Lymphoid Blast Crisis. *Blood*, **2012**, 120, 34-34 2.2
- 11 Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia.. *Blood*, **2012**, 120, 2565-2565 2.2
- 10 Identification of FoxM1 As Therapeutic Target in TKI-Resistant Ph+ ALL. *Blood*, **2012**, 120, 874-874 2.2
- 9 Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL. *Blood*, **2012**, 120, 528-528 2.2
- 8 Cooperation Between Aid and the Rag1/Rag2 V(D)J Recombinase Drives Clonal Evolution of Childhood Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 519-519 2.2
- 7 Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 349-349 2.2
- 6 Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia. *Blood*, **2013**, 122, 229-229 2.2
- 5 Normal ABL1 Is a Tumor Suppressor and Therapeutic Target In BCR-ABL1 β positive Leukemias. *Blood*, **2013**, 122, 1466-1466 2.2
- 4 Identification Of FOXM1 As Therapeutic Target In BCR-ABL1 Positive Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 1250-1250 2.2
- 3 The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL. *Blood*, **2013**, 122, 836-836 2.2
- 2 Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL. *Blood*, **2013**, 122, 72-72 2.2
- 1 Metabolic determinants of B-cell selection. *Biochemical Society Transactions*, **2021**, 49, 1467-1478 5.1